The Latest on Ketamine and Esketamine for Treatment Resistant Depression

Current Status
Not Enrolled
Get Started
Get access to these and all of our healthcare courses with the Unlimited Nursing CEU Subscription.
Learn More

Customers Also Bought

Course bundles are currently available for individuals only.

Course Description

Depression is a global, widespread mental health disorder, affecting 350 million people. For some, current treatment modalities are not sufficient to support patient needs. This continuing education program will review and synthesize current evidence about the use of glutamate receptor modular medications (ketamine and esketamine) for treatment resistant depression. These medications have shown rapid and significant lifting of mood and suicidal ideation in symptomatic patients. An in-depth discussion of adverse effects, patient selection, treatment and administration protocols, and concerns for patient safety will be presented.

Intended Audience

  • Physicians
  • Nurses
  • Advanced Practice Nurses
  • Physicians Assistants
  • Pharmacists
  • Psychologists
  • Other Allied Health

Learning Objectives

At the completion of this activity, healthcare providers will be able to: 

  • Explain the burden of depressive disorders as a chronic, relapsing condition, and their associated costs, morbidity, and mortality
  • Provide a brief synopsis of the proposed mechanism of action, pharmacodynamics, and pharmacokinetics for glutamate receptor modulators to treat TRD and major depression with suicidal ideation
  • Evaluate the efficacy of ketamine and esketamine to produce a meaningful response in individuals with TRD and major depression with suicidal ideation
  • Interpret dosing regimens, with attention to the risks, benefits, costs, barriers, and burdens
  • Summarize the incidence and management of adverse effects associated with the psychiatric use of ketamine/esketamine therapy
  • Determine appropriate patient selection, setting, personnel, and monitoring for safe administration and security in a clinical setting
  • Assess items from safety tools, such as the Risk Evaluation and Mitigation Strategy (REMS) in creating a safety net and best practices for administering ketamine and esketamine
  • Outline the concerns over misuse and diversion of ketamine/esketamine
  • Identify future research and clinical practice guideline directions needed to improve the wide-ranging concerns and implications for using ketamine and esketamine for TRD and major depression with suicidal ideation
Credit/Contact Hours
Pharmacotherapy Hours
  • Kathy Gardner, DNP, APRN, FNP-BC, CNM, CNE
    Faculty, Frontier Nursing University
  • English
Release Date
February 1, 2023
Expiration Date
February 1, 2026
Instructional Methods
  • Assessment Review with Rationale
  • Case Studies
  • Ungraded Self Assessment-Lesson Recall
  • Video Clips
  • Video Narration
  • Autograded and Quiz Retakes Allowed
  • Daily CE Broker Reporting for Registered Boards
  • Graded Final Quiz
  • Passing 80%+
Shopping Cart
Scroll to Top